Merck's Acquisition of EyeBio Finalized
Merck's Acquisition of EyeBio Finalized
Merck (NYSE:MRK) is trending on Friday. The company announced the acquisition of EyeBio, introducing a novel candidate to Merk's pipeline, Restoret.
默沙东（纽交所：MRK）正在本周五受关注。该公司宣布收购眼科公司EyeBio，引入了一个新的候选药物Restoret到默沙东的管线中。
What To Know: Restoret has shown promising results in a Phase 1b/2a AMARONE study in participants with diabetic macular edema (DME) and neovascular age-related macular degeneration (NVAMD).
了解一下：Restoret在1b/2a AMARONE研究中向参与人员展示了有希望的结果，适用于糖尿病性黄斑水肿（DME）和新生老年性黄斑变性（NVAMD）
The treatment is anticipated to advance to a Phase 2b/3 trial to further assess its potential as a treatment for DME later this year.
该治疗预计将在今年晚些时候进入2b/3期试验，以进一步评估其作为DME治疗方法的潜力。
"The EyeBio acquisition further diversifies our late-stage pipeline with the addition of a promising candidate based on novel biology and genetics for the treatment of certain retinal diseases," said Dean Y. Li, president, Merck Research Laboratories. "We are excited to welcome the EyeBio team and look forward to working together to advance Restoret for the patients that need it."
"通过基于新的生物学和遗传学的有前途的候选药物，收购EyeBio进一步使我们的后期阶段管线多样化，用于治疗某些视网膜疾病。"默沙东研究实验室的总裁Dean Y. Li说:"我们很兴奋能够欢迎EyeBio团队，并期待着与他们合作，推进Restoret为需要它的患者服务。"
Other potential pipeline candidates consist of clinical and preclinical assets being developed to prevent and treat vision loss linked to retinal vascular leakage, which is a recognized risk factor for retinal diseases.
其他可能的管线候选药物包括正在开发用于预防和治疗与视网膜血管渗漏相关的视力损失的临床和临床前资产。这是许多视网膜疾病的公认风险因素。
MRK Price Action: At the time of writing, Merck stock is trading 0.57% lower at $128.22, according to data from Benzinga Pro.
MRK股价变动：根据Benzinga Pro的数据，撰写本文时，默克股票交易价格为128.22美元，较低0.57%。
Image: Photo via Company
图片：通过公司提供的照片